Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal...
-
Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas Ocuphire Presenting Nyxol® + Low Dose...
-
FARMINGTON HILLS, Mich., July 09, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely...
-
Met primary endpoint with statistical significance at 1 hour with 61% of subjects treated with Nyxol® plus low-dose pilocarpine (LDP) gaining ≥ 15 letters (3 lines) in near vision Key secondary...
-
FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of...
-
FARMINGTON HILLS, Mich., June 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of...
-
FARMINGTON HILLS, Mich., June 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
-
Highlights of Recent Positive Data from Nyxol’s Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient Populations Webinar on Wednesday, May 26th @...
-
Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol® Combination Therapy for Presbyopia Provides Broader Protection for Nyxol® Across Indications on Methods of Use as Daily...